# Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA)

> **NCT03606590** · PHASE2 · COMPLETED · sponsor: **NovoCure Ltd.** · enrollment: 25 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DEVICE:** NovoTTF-100L(P) device
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT03606590
- **Lead sponsor:** NovoCure Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-15
- **Primary completion:** 2021-01-14
- **Final completion:** 2021-01-14
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2024-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03606590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03606590, "Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03606590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*